These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

436 related items for PubMed ID: 9382122

  • 1. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis.
    Thiébaud D, Burckhardt P, Kriegbaum H, Huss H, Mulder H, Juttmann JR, Schöter KH.
    Am J Med; 1997 Oct; 103(4):298-307. PubMed ID: 9382122
    [Abstract] [Full Text] [Related]

  • 2. The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study.
    Ravn P, Clemmesen B, Riis BJ, Christiansen C.
    Bone; 1996 Nov; 19(5):527-33. PubMed ID: 8922653
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
    Emkey R, Delmas PD, Bolognese M, Borges JL, Cosman F, Ragi-Eis S, Recknor C, Zerbini CA, Neate C, Sedarati F, Epstein S.
    Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
    [Abstract] [Full Text] [Related]

  • 4. Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women.
    Stakkestad JA, Benevolenskaya LI, Stepan JJ, Skag A, Nordby A, Oefjord E, Burdeska A, Jonkanski I, Mahoney P, Ibandronate Intravenous Study Group.
    Ann Rheum Dis; 2003 Oct; 62(10):969-75. PubMed ID: 12972476
    [Abstract] [Full Text] [Related]

  • 5. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
    McClung MR, Wasnich RD, Recker R, Cauley JA, Chesnut CH, Ensrud KE, Burdeska A, Mills T, Oral Ibandronate Study Group.
    J Bone Miner Res; 2004 Jan; 19(1):11-8. PubMed ID: 14753731
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study.
    Eisman JA, Civitelli R, Adami S, Czerwinski E, Recknor C, Prince R, Reginster JY, Zaidi M, Felsenberg D, Hughes C, Mairon N, Masanauskaite D, Reid DM, Delmas PD, Recker RR.
    J Rheumatol; 2008 Mar; 35(3):488-97. PubMed ID: 18260172
    [Abstract] [Full Text] [Related]

  • 7. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study.
    Miller PD, Epstein S, Sedarati F, Reginster JY.
    Curr Med Res Opin; 2008 Jan; 24(1):207-13. PubMed ID: 18042311
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of ibandronate given by intravenous injection once every 3 months.
    Adami S, Felsenberg D, Christiansen C, Robinson J, Lorenc RS, Mahoney P, Coutant K, Schimmer RC, Delmas PD.
    Bone; 2004 May; 34(5):881-9. PubMed ID: 15121020
    [Abstract] [Full Text] [Related]

  • 9. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study.
    Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster JY, Felsenberg D, Christiansen C, Civitelli R, Drezner MK, Recker RR, Bolognese M, Hughes C, Masanauskaite D, Ward P, Sambrook P, Reid DM.
    Arthritis Rheum; 2006 Jun; 54(6):1838-46. PubMed ID: 16729277
    [Abstract] [Full Text] [Related]

  • 10. Infusion of ibandronate once every 3 months effectively decreases bone resorption markers and increases bone mineral density in Chinese postmenopausal osteoporotic women: a 1-year study.
    Li M, Xing XP, Zhang ZL, Liu JL, Zhang ZL, Liu DG, Xia WB, Meng XW.
    J Bone Miner Metab; 2010 May; 28(3):299-305. PubMed ID: 19855926
    [Abstract] [Full Text] [Related]

  • 11. Oral weekly ibandronate prevents bone loss in postmenopausal women.
    Tankó LB, Felsenberg D, Czerwiński E, Burdeska A, Jonkanski I, Hughes C, Christiansen C, Oral Ibandronate Group.
    J Intern Med; 2003 Aug; 254(2):159-67. PubMed ID: 12859697
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of monthly ibandronate in men with low bone density.
    Orwoll ES, Binkley NC, Lewiecki EM, Gruntmanis U, Fries MA, Dasic G.
    Bone; 2010 Apr; 46(4):970-6. PubMed ID: 20060082
    [Abstract] [Full Text] [Related]

  • 13. The efficacy of 48-week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60 minutes before breakfast.
    Tankó LB, McClung MR, Schimmer RC, Mahoney P, Christiansen C.
    Bone; 2003 Apr; 32(4):421-6. PubMed ID: 12689686
    [Abstract] [Full Text] [Related]

  • 14. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
    Chesnut CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD, Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE).
    J Bone Miner Res; 2004 Aug; 19(8):1241-9. PubMed ID: 15231010
    [Abstract] [Full Text] [Related]

  • 15. Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies.
    Schimmer RC, Bauss F.
    Clin Ther; 2003 Jan; 25(1):19-34. PubMed ID: 12637110
    [Abstract] [Full Text] [Related]

  • 16. Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial.
    Hakala M, Kröger H, Valleala H, Hienonen-Kempas T, Lehtonen-Veromaa M, Heikkinen J, Tuomiranta T, Hannonen P, Paimela L, ONCE trial group.
    Scand J Rheumatol; 2012 Aug; 41(4):260-6. PubMed ID: 22803768
    [Abstract] [Full Text] [Related]

  • 17. Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis.
    Lewiecki EM, Keaveny TM, Kopperdahl DL, Genant HK, Engelke K, Fuerst T, Kivitz A, Davies RY, Fitzpatrick LA.
    J Clin Endocrinol Metab; 2009 Jan; 94(1):171-80. PubMed ID: 18840641
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss.
    McClung MR, Bolognese MA, Sedarati F, Recker RR, Miller PD.
    Bone; 2009 Mar; 44(3):418-22. PubMed ID: 18950736
    [Abstract] [Full Text] [Related]

  • 19. Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension.
    Bianchi G, Czerwinski E, Kenwright A, Burdeska A, Recker RR, Felsenberg D.
    Osteoporos Int; 2012 Jun; 23(6):1769-78. PubMed ID: 21975558
    [Abstract] [Full Text] [Related]

  • 20. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study.
    Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B, Reginster JY, Recker RR, Hughes C, Lewiecki EM, Felsenberg D, Delmas PD, Kendler DL, Bolognese MA, Mairon N, Cooper C.
    J Bone Miner Res; 2005 Aug; 20(8):1315-22. PubMed ID: 16007327
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.